<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EPIRUBICIN HYDROCHLORIDE- epirubicin hydrochloride injection, solution </strong><br>Greenstone, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Epirubicin HCl safely and effectively. See full prescribing information for Epirubicin HCl.<br> <br>Epirubicin HCl (epirubicin hydrochloride injection)<br>Initial U.S. Approval: 1999</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SEVERE OR LIFE-THREATENING HEMATOLOGICAL AND OTHER ADVERSE REACTIONS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li>Severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> associated with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> during administration (<a href="#S5.9">5.9</a>)</li>
<li>Myocardial toxicity, manifested in its most severe form by potentially fatal <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) (<a href="#S5.3">5.3</a>)</li>
<li>Secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) (<a href="#S5.4">5.4</a>)</li>
<li>Reduce dosage in patients with impaired hepatic function (<a href="#S5.5">5.5</a>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (<a href="#S5.2">5.2</a>)</li>
<li>Administer only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents (<a href="#S5">5</a>)</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="85%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"><a href="#BOX">Boxed Warning</a></td>
<td align="right">09/2011</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Preparation and Administration (<a href="#S2.3">2.3</a>)</td>
<td align="right">09/2011</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Injection-Related Reactions, Hematologic, Cardiac, Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span>, Coadministration with Cimetidine, Pregnancy, Male Fertility and Reproductive Outcomes, laboratory Testing, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> following Irradiation (<a href="#S5.1">5.1</a>, <a href="#S5.2">5.2</a>, <a href="#S5.3">5.3</a>, <a href="#S5.4">5.4</a>, <a href="#S5.11">5.11</a>, <a href="#S5.12">5.12</a>, <a href="#S5.13">5.13</a>, <a href="#S5.14">5.14</a>, <a href="#S5.15">5.15</a>)</td>
<td align="right">09/2011</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Male Fertility and Reproductive Outcomes (<a href="#S5.13">5.13</a>)</td>
<td align="right">11/2011</td>
</tr>
<tr class="Botrule Last">
<td align="left">Drug Interactions, Cadioactive Compounds, cimetidine, other Cytotoxic Drugs, Radiation Therapy, Concomitant Therapies-Hepatic Function (<a href="#S7.1">7.1</a>, <a href="#S7.2">7.2</a>, <a href="#S7.3">7.3</a>, <a href="#S7.4">7.4</a>, <a href="#S7.5">7.5</a>)</td>
<td align="right">09/2011</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SEVERE OR LIFE-THREATENING HEMATOLOGICAL AND OTHER ADVERSE REACTIONS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li>Severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> associated with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> during administration (<a href="#S5.9">5.9</a>)</li>
<li>Myocardial toxicity, manifested in its most severe form by potentially fatal <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) (<a href="#S5.3">5.3</a>)</li>
<li>Secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) (<a href="#S5.4">5.4</a>)</li>
<li>Reduce dosage in patients with impaired hepatic function (<a href="#S5.5">5.5</a>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (<a href="#S5.2">5.2</a>)</li>
<li>Administer only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents (<a href="#S5">5</a>)</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Epirubicin HCl Injection is an anthracycline topoisomerase II inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer (<a href="#S1">1.1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Administer intravenously in repeated 3- to 4-week cycles, either total dose on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle (<a href="#S2">2</a>).</li>
<li>The recommended starting dose of Epirubicin HCl is 100 to 120 mg/m<span class="Sup">2.</span> Dosage reductions are possible when given in certain combinations (<a href="#S2.1">2.1</a>).</li>
<li>Dosage adjustments after the first treatment cycle should be made based on hematologic and nonhematologic toxicities (<a href="#S2.2">2.2</a>).</li>
<li>Reduce dose in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#S2.2">2.2</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>).</li>
<li>Consider lower doses in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>  (<a href="#S2.2">2.2</a>, <a href="#S8.7">8.7</a>,<a href="#S12.3">12.3</a>).</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single use vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use solution (50 mg/25 mL and 200 mg/100 mL) (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients should not be treated with Epirubicin HCl Injection if they have any of the following conditions: baseline neutrophil count &lt; 1500 cells/mm<span class="Sup">3;</span> severe myocardial insufficiency, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>; previous treatment with anthracyclines up to the maximum cumulative dose; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to epirubicin, other anthracyclines, or anthracenediones; or severe hepatic dysfunction (<a href="#S4">4</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>A dose-dependent, reversible <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is the predominant manifestation of hematologic toxicity associated with Epirubicin HCl and represents the most common acute dose-limiting toxicity (<a href="#S5.2">5.2</a>).</li>
<li>Cardiotoxicity is a known risk of anthracycline treatment and may be manifested by early (or acute) or late (delayed) events (<a href="#S5.3">5.3</a>).</li>
<li>The occurrence of secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, with or without a preleukemic phase, has been reported in patients treated with anthracyclines (<a href="#S5.4">5.4</a>).</li>
<li>Serum total bilirubin and AST levels should be evaluated before and during treatment with Epirubicin HCl. Patients with elevated bilirubin or AST may experience slower clearance of drug with an increase in overall toxicity. Lower doses are recommended in these patients. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been evaluated (<a href="#S5.5">5.5</a>).</li>
<li>Serum creatinine should be assessed before and during therapy. Dosage adjustment is necessary in patients with serum creatinine &gt;5 mg/dL. Patients undergoing dialysis have not been studied (<a href="#S5.6">5.6</a>).</li>
<li>Epirubicin HCl may induce <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> as a consequence of the extensive purine catabolism that accompanies drug-induced rapid lysis of highly chemosensitive neoplastic cells (tumor-lysis syndrome) (<a href="#S5.7">5.7</a>).</li>
<li>Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including Epirubicin HCl, may result in serious or fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#S5.8">5.8</a>).</li>
<li>Venous sclerosis may result from an injection into a small vessel or from repeated injections into the same vein. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of Epirubicin HCl during the infusion may cause local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, severe tissue lesions (vesication, severe <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>), and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>. <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Facial flushing</span>, as well as local erythematous streaking along the vein, may be indicative of excessively rapid administration. It may precede local <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> or <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. Patients administered the 120-mg/m<span class="Sup">2 </span>regimen of Epirubicin HCl as a component of combination chemotherapy should also receive <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotic therapy with trimethoprim-sulfamethoxazole (e.g., Septra®, Bactrim®) or a fluoroquinolone (<a href="#S5.9">5.9</a>).</li>
<li>Epirubicin HCl is emetigenic. Antiemetics may reduce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of antiemetics should be considered before administration of Epirubicin HCl, particularly when given in conjunction with other emetigenic drugs (<a href="#S5.10">5.10</a>).</li>
<li>Administration of Epirubicin HCl after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation (<a href="#S5.11">5.11</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> and thromboembolic phenomena, including <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (in some cases fatal) have been coincidentally reported with the use of Epirubicin HCl (<a href="#S5.12">5.12</a>).</li>
<li>Epirubicin HCl can cause fetal harm when administered to a pregnant woman. Advise women of potential risk to the fetus (<a href="#S5.12">5.12</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>In early breast cancer, acute adverse events occurring in ≥10% of patients are <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, amenhorrhea, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>/<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, local toxicity and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span> (<a href="#S6">6</a>).</li>
<li>Long term adverse events occurring at a frequency of 1–2% are asymptomatic drops in LVEF and CHF and secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (<a href="#S6">6</a>).</li>
</ul>
<br><p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch</span><span class="Italics">.</span> </p>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Do not administer Epirubicin in combination with other cardiotoxic agents unless the patient's cardiac function is closely monitored (<a href="#S7.1">7.1</a>).</li>
<li>Stop Cimetidine during treatment with Epirubicin HCl (<a href="#S7.2">7.2</a>).</li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Nursing Mothers: Discontinue nursing prior to taking Epirubicin HCl (<a href="#S8.3">8.3</a>).</li>
<li>Pediatric Use: Safety and effectiveness of Epirubicin HCl in pediatric patients have not been established. Pediatric patients may be at greater risk for anthracycline-induced acute manifestations of cardiotoxicity and for chronic CHF (<a href="#S8.4">8.4</a>).</li>
<li>Geriatric Use: Care should be taken in monitoring toxicity when Epirubicin HCl is administered to female patients ≥ 70 years of age. (<a href="#S8.5">8.5</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING:  RISK OF TISSUE <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">NECROSIS</span>, CARDIAC TOXICITY, SECONDARY ACUTE MYELOGENOUS <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">LEUKEMIA</span>, AND <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2      Dose Modifications</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Preparation and Administration Precautions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Injection-Related Reactions</a></h2>
<h2><a href="#section-5.2" class="toc">5.2      Hematologic</a></h2>
<h2><a href="#section-5.3" class="toc">5.3    Cardiac</a></h2>
<h2><a href="#section-5.4" class="toc">5.4     Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5      Hepatic</a></h2>
<h2><a href="#section-5.6" class="toc">5.6     Renal</a></h2>
<h2><a href="#section-5.7" class="toc">5.7     Tumor-Lysis Syndrome</a></h2>
<h2><a href="#section-5.8" class="toc">5.8     Immunosuppressant Effects/Increased Susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9     Gastrointestinal</a></h2>
<h2><a href="#section-5.10" class="toc">5.10    <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> and Thromboembolic Phenomena</a></h2>
<h2><a href="#section-5.11" class="toc">5.11     Coadministration with Cimetidine</a></h2>
<h2><a href="#section-5.12" class="toc">5.12	Pregnancy</a></h2>
<h2><a href="#section-5.13" class="toc">5.13    Male Fertility and Reproductive Outcomes</a></h2>
<h2><a href="#section-5.14" class="toc">5.14    Laboratory Testing</a></h2>
<h2><a href="#section-5.15" class="toc">5.15    <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> following Irradiation</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1      Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Overview of Acute and Delayed Toxicities</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1   Cardioactive Compounds</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Cimetidine</a></h2>
<h2><a href="#section-7.3" class="toc">7.3    Other Cytotoxic Drugs</a></h2>
<h2><a href="#section-7.4" class="toc">7.4     Radiation Therapy</a></h2>
<h2><a href="#section-7.5" class="toc">7.5     Concomitant Therapies-Hepatic Function</a></h2>
<h2><a href="#section-7.6" class="toc">7.6       Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7   <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adjuvant Treatment of Breast Cancer</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1>WARNING:  RISK OF TISSUE <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">NECROSIS</span>, CARDIAC TOXICITY, SECONDARY ACUTE MYELOGENOUS <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">LEUKEMIA</span>, AND <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></h1>
<p class="First"><span class="Bold">RISK OF TISSUE <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">NECROSIS</span>, CARDIAC TOXICITY, SECONDARY ACUTE MYELOGENOUS <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">LEUKEMIA</span>, AND <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></span></p>
<ol>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">Severe local tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> will occur if there is <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> during administration. Epirubicin HCl must not be given by the intramuscular or subcutaneous route<span class="Italics"> [see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</span></li>
<li>Cardiac toxicity, including fatal <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF), may occur either during therapy with Epirubicin HCl or months to years after termination of therapy. The probability of developing clinically evident CHF is estimated as approximately 0.9% at a cumulative dose of 550 mg/m<span class="Sup">2</span>, 1.6% at 700 mg/m<span class="Sup">2</span>, and 3.3% at 900 mg/m<span class="Sup">2</span>. In the adjuvant treatment of breast cancer, the maximum cumulative dose used in clinical trials was 720 mg/m<span class="Sup">2</span>. The risk of developing CHF increases rapidly with increasing total cumulative doses of Epirubicin HCl in excess of 900 mg/m<span class="Sup">2</span>; this cumulative dose should only be exceeded with extreme caution. Active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic drugs may increase the risk of cardiac toxicity. Cardiac toxicity with Epirubicin HCl may occur at lower cumulative doses whether or not cardiac risk factors are present <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span>
</li>
<li>Secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) has been reported in patients with breast cancer treated with anthracyclines, including epirubicin. The occurrence of refractory secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> is more common when such drugs are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. The cumulative risk of developing treatment-related AML or <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (MDS), in 7110 patients with breast cancer who received adjuvant treatment with Epirubicin HCl-containing regimens, was estimated as 0.27% at 3 years, 0.46% at 5 years, and 0.55% at 8 years <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>].</span>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may occur <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Epirubicin HCl Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">When possible, to reduce the risk of developing cardiotoxicity in patients receiving Epirubicin HCl after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, Epirubicin HCl-based therapy should be delayed until the other agents have cleared from the circulation <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span></p>
<p>Administer Epirubicin HCl Injection by intravenous infusion. Give Epirubicin HCl in repeated 3- to 4-week cycles. The total dose of Epirubicin HCl may be given on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle. The recommended dosages of Epirubicin HCl are as follows:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dose</h2>
<p class="First">The recommended dose of Epirubicin HCl is 100 to 120 mg/m<span class="Sup">2</span>. The following regimens are recommended: </p>
<table width="90%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="30%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">CEF-120:</td>
<td align="left">Cyclophosphamide</td>
<td align="left">75 mg/m<span class="Sup">2</span> PO D 1–14</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">Epirubicin HCl</td>
<td align="left">60 mg/m<span class="Sup">2</span> IV D 1, 8</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">5-Fluorouracil</td>
<td align="left">500 mg/m<span class="Sup">2</span> IV D 1, 8</td>
</tr>
<tr>
<td align="left"></td>
<td align="left" colspan="2">Repeated every 28 days for 6 cycles</td>
</tr>
<tr>
<td align="left">FEC-100:</td>
<td align="left">5-Fluorouracil</td>
<td align="left">500 mg/m<span class="Sup">2</span>
</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">Epirubicin HCl</td>
<td align="left">100 mg/m<span class="Sup">2</span>
</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">Cyclophosphamide</td>
<td align="left">500 mg/m<span class="Sup">2</span>
</td>
</tr>
<tr class="Botrule Last">
<td align="left"></td>
<td align="left" colspan="2">All drugs administered intravenously on Day 1 and repeated every 21 days for 6 cycles</td>
</tr>
</tbody>
</table>
<p>Patients administered the 120-mg/m<span class="Sup">2</span> regimen of Epirubicin HCl should receive <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotic therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2      Dose Modifications</h2>
<p class="First">Epirubicin HCl dosage adjustments for hematologic and non-hematologic toxicities within a cycle of treatment, is based on nadir platelet counts &lt;50,000/mm<span class="Sup">3</span>, absolute neutrophil counts (ANC) &lt;250/mm<span class="Sup">3</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>, or Grades 3/4 nonhematologic toxicity. Reduce Epirubicin HCl Day 1 dose in subsequent cycles to 75% of the Day 1 dose given in the current cycle. Delay Day 1 chemotherapy in subsequent courses of treatment until platelet counts are ≥100,000/mm<span class="Sup">3</span>, ANC  ≥1500/mm<span class="Sup">3</span>, and nonhematologic toxicities have recovered to ≤ Grade 1.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Italics">Bone Marrow Dysfunction </span></p>
<p>Consider administering a lower starting dose (75–90 mg/m<span class="Sup">2</span>) for heavily pretreated patients, patients with pre-existing <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, or in the presence of neoplastic bone marrow infiltration <span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a>].</span> For patients receiving a divided dose of Epirubicin HCl (Day 1 and Day 8), the Day 8 dose should be 75% of Day 1 if platelet counts are 75,000–100,000/mm<span class="Sup">3</span> and ANC is 1000 to 1499/mm<span class="Sup">3</span>. If Day 8 platelet counts are &lt;75,000/mm<span class="Sup">3</span>, ANC &lt;1000/mm<span class="Sup">3</span>, or Grades 3/4 nonhematologic toxicity has occurred, omit the Day 8 dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></p>
<p>Recommendations regarding use of Epirubicin HCl in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> are not available because patients with hepatic abnormalities were not included in the adjuvant trials <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. In patients with elevated serum AST or serum total bilirubin concentrations, the following dose reductions are recommended:</p>
<ul>
<li> Bilirubin 1.2 to 3 mg/dL or AST 2 to 4 times upper limit of normal 1/2 of recommended starting dose</li>
<li> Bilirubin &gt; 3 mg/dL or AST &gt; 4 times upper limit of normal 1/4 of recommended starting dose</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.3"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>While no specific dose recommendation can be made based on the limited available data in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, consider lower doses in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (serum creatinine &gt; 5 mg/dL) <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Preparation and Administration Precautions</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15–25ºC).</span></p>
<p>Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Procedures for proper handling and disposal of anticancer drugs should be used when handling and preparing Epirubicin HCl. Several guidelines on this subject have been published.<span class="Sup">1–4 </span><span class="Italics">[see <a href="#S15">References (15)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Italics">Protective Measures</span></p>
<p>Take the following protective measures when handling Epirubicin HCl:</p>
<ul>
<li>Train personnel in appropriate techniques for reconstitution and handling.</li>
<li>Exclude pregnant staff from working with this drug.</li>
<li>Wear protective clothing: goggles, gowns, and disposable gloves and masks when handling Epirubicin HCl.</li>
<li>Define a designated area for syringe preparation (preferably under a laminar flow system), with the work surface protected by disposable, plastic-backed, absorbent paper.</li>
<li>Place all items used for reconstitution, administration, or cleaning (including gloves) in high-risk, waste-disposal bags for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperature</span> incineration.</li>
<li>Treat spillage or leakage with dilute sodium hypochlorite (1% available chlorine) solution, preferably by soaking, and then water. Place all contaminated and cleaning materials in high-risk, waste-disposal bags for incineration. Treat accidental contact with the skin or eyes immediately by copious lavage with water, or soap and water, or sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> solution. However, do not abrade the skin by using a scrub brush. Seek medical attention. Always wash hands after removing gloves.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Bold"> Incompatibilities</span></p>
<p>Avoid prolonged contact with any solution of an alkaline pH as it will result in hydrolysis of the drug. Do not mix Epirubicin HCl with heparin or fluorouracil due to chemical incompatibility that may lead to precipitation.</p>
<p>Epirubicin HCl can be used in combination with other antitumor agents, but do not mix with other drugs in the same syringe.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.3"></a><p></p>
<p class="First"><span class="Bold"> Preparation of Infusion Solution</span></p>
<p>Administer Epirubicin HCl into the tubing of a freely flowing intravenous infusion (0.9% sodium chloride or 5% glucose solution). Patients receiving initial therapy at the recommended starting doses of 100–120 mg/m<span class="Sup">2</span> should generally have Epirubicin HCl infused over 15–20 minutes. For patients who require lower Epirubicin HCl starting doses due to organ dysfunction or who require modification of Epirubicin HCl doses during therapy, the Epirubicin HCl infusion time may be proportionally decreased, but should not be less than 3 minutes. This technique is intended to minimize the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or perivenous <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, which could lead to severe <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, vesication, or tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>. A direct push injection is not recommended due to the risk of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, which may occur even in the presence of adequate blood return upon needle <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Venous sclerosis may result from injection into small vessels or repeated injections into the same vein <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>].</span> Use Epirubicin HCl within 24 hours of first penetration of the rubber stopper. Discard any unused solution.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Epirubicin HCl is provided in polypropylene single-use CYTOSAFE™ vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use solution in the following sizes: 50 mg/25 mL and 200 mg/100 mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Patients should not be treated with Epirubicin HCl Injection if they have any of the following conditions:</p>
<p>Severe myocardial insufficiency, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span></p>
<p>Previous treatment with maximum cumulative dose of anthracyclines <span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a>]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Epirubicin HCl, other anthracyclines, or anthracenediones <span class="Italics">[see <a href="#S6.2">Adverse Reactions (6.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">Administer Epirubicin HCl Injection only under the supervision of qualified physicians experienced in the use of cytotoxic therapy. Before beginning treatment with Epirubicin HCl, patients should recover from acute toxicities (such as <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and generalized <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>) of prior cytotoxic treatment. Also, precede initial treatment with Epirubicin HCl by a careful baseline assessment of blood counts; serum levels of total bilirubin, AST, and creatinine; and cardiac function as measured by left ventricular ejection function (LVEF). Carefully monitor patients during treatment for possible clinical complications due to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Supportive care may be necessary for the treatment of severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and severe infectious complications. Monitoring for potential cardiotoxicity is also important, especially with greater cumulative exposure to Epirubicin HCl.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Injection-Related Reactions</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Epirubicin HCl Injection is administered by intravenous infusion. Venous sclerosis may result from an injection into a small vessel or from repeated injections into the same vein. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of Epirubicin HCl during the infusion may cause local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, severe tissue lesions (vesication, severe <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>), and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>. Administer Epirubicin HCl slowly into the tubing of a freely running intravenous infusion. Patients receiving initial therapy at the recommended starting doses of 100–120 mg/m<span class="Sup">2</span> should generally have Epirubicin HCl infused over 15–20 minutes. For patients who require lower Epirubicin HCl starting doses due to organ dysfunction or who require modification of Epirubicin HCl doses during therapy, the Epirubicin HCl infusion time may be proportionally decreased, but should not be less than 3 minutes. <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>].</span> If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage. Immediately terminate infusion and restart in another vein if a burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> sensation indicates perivenous infiltration. Perivenous infiltration may occur without causing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Facial flushing</span>, as well as local erythematous streaking along the vein, may be indicative of excessively rapid administration. It may precede local <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> or <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>. Give <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotic therapy to patients administered the 120-mg/m<span class="Sup">2</span> regimen of Epirubicin HCl as a component of combination chemotherapy <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a> and <a href="#S2.1">Dosage and Administration 2.1)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2      Hematologic</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Epirubicin HCl can suppress bone marrow function as manifested by <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is usually the dose-limiting toxicity. Patients should be monitored for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> during therapy <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2</a>, <a href="#S2.3">2.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3    Cardiac</h2>
<p class="First">Cardiotoxicity is a known risk of anthracycline treatment. Anthracycline-induced cardiac toxicity may be manifested by early (or acute) or late (delayed) events. Early cardiac toxicity of Epirubicin HCl consists mainly of <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span> and/or electrocardiogram (ECG) abnormalities such as non-specific ST-T wave changes, but <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span> and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, as well as atrioventricular and bundle-branch block have also been reported. These effects do not usually predict subsequent development of delayed cardiotoxicity, are rarely of clinical importance, and are generally not considered an indication for the suspension of Epirubicin HCl treatment. Delayed cardiac toxicity results from a characteristic <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> that is manifested by reduced LVEF and/or signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="319927" conceptname="Heart sounds abnormal">gallop rhythm</span>. Life-threatening CHF is the most severe form of anthracycline-induced <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. This toxicity appears to be dependent on the cumulative dose of Epirubicin HCl and represents the cumulative dose-limiting toxicity of the drug. If it occurs, delayed cardiotoxicity usually develops late in the course of therapy with Epirubicin HCl or within 2 to 3 months after completion of treatment, but later events (several months to years after treatment termination) have been reported. </p>
<p>Given the risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, exceed a cumulative dose of 900 mg/m<span class="Sup">2</span> Epirubicin HCl only with extreme caution. Risk factors [active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, concomitant use of other drugs with the ability to suppress cardiac contractility or cardiotoxic drugs, especially those with long half-lives (e.g., trastuzumab)] may increase the risk of Epirubicin HCl cardiotoxicity <span class="Italics">[see <a href="#S7.4">Drug Interaction (7.4)</a> and <a href="#S2">Dosage and Administration (2)</a>].</span> Although not formally tested, it is probable that the toxicity of Epirubicin HCl and other anthracyclines or anthracenediones is additive. Cardiac toxicity with Epirubicin HCl may occur at lower cumulative doses whether or not cardiac risk factors are present. </p>
<p>Although endomyocardial biopsy is recognized as the most sensitive diagnostic tool to detect anthracycline-induced <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, this invasive examination is not practically performed on a routine basis. ECG changes such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>, a reduction of the QRS voltage, or a prolongation beyond normal limits of the systolic time interval may be indicative of anthracycline-induced <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, but ECG is not a sensitive or specific method for following anthracycline-related cardiotoxicity. The risk of serious cardiac impairment may be decreased through regular monitoring of LVEF during the course of treatment with prompt discontinuation of Epirubicin HCl at the first sign of impaired function. The preferred method for repeated assessment of cardiac function is evaluation of LVEF measured by multi-gated radionuclide angiography (MUGA) or echocardiography (ECHO). A baseline cardiac evaluation with an ECG and a MUGA scan or an ECHO is recommended, especially in patients with risk factors for increased cardiac toxicity. Perform repeated MUGA or ECHO determinations of LVEF, particularly with higher, cumulative anthracycline doses. The technique used for assessment should be consistent through follow-up. In patients with risk factors, particularly prior anthracycline or anthracenedione use, the monitoring of cardiac function must be particularly strict and the risk-benefit of continuing treatment with Epirubicin HCl in patients with impaired cardiac function must be carefully evaluated.</p>
<p style="border-left:1px solid;"><span class="XmChange">Do not administer Epirubicin HCl in combination with other cardiotoxic agents unless the patient's cardiac function is closely monitored. Patients receiving Epirubicin HCl after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, may also be at an increased risk of developing cardiotoxicity. Avoid Epirubicin HCl-based therapy for up to 24 weeks after stopping trastuzumab when possible. If Epirubicin HCl is used before this time, monitor cardiac function carefully <span class="Italics">[see <a href="#S2">Dosage and Administration (2)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4     Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The occurrence of secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, with or without a preleukemic phase, has been reported in patients treated with anthracyclines. Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> is more common when such drugs are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic drugs, or when doses of the anthracyclines have been escalated. These <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> can have a short 1- to 3-year latency period.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Epirubicin HCl is mutagenic, clastogenic, and carcinogenic in animals <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5      Hepatic</h2>
<p class="First">The major route of elimination of epirubicin is the hepatobiliary system <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Evaluate serum total bilirubin and AST levels before and during treatment with Epirubicin HCl. Patients with elevated bilirubin or AST may experience slower clearance of drug with an increase in overall toxicity. Lower doses are recommended in these patients <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been evaluated; therefore, do not use Epirubicin HCl in this patient population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6     Renal</h2>
<p class="First">Assess serum creatinine before and during therapy. Dosage adjustment is necessary in patients with serum creatinine &gt;5 mg/dL [<span class="Italics">see </span><span class="Italics"><a href="#S2.2">Dosage and Administration (2.2)</a></span>]. Patients undergoing dialysis have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7     Tumor-Lysis Syndrome</h2>
<p class="First">As with other cytotoxic agents, Epirubicin HCl may induce <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> as a consequence of the extensive purine catabolism that accompanies drug-induced rapid lysis of highly chemosensitive neoplastic cells (tumor-lysis syndrome). Other metabolic abnormalities may also occur. While not generally a problem in patients with breast cancer, consider the potential for tumor-lysis syndrome in potentially susceptible patients and consider monitoring serum uric acid, potassium, calcium, phosphate, and creatinine immediately after initial chemotherapy administration. Hydration, urine alkalinization, and prophylaxis with allopurinol to prevent <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> may minimize potential complications of tumor-lysis syndrome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8     Immunosuppressant Effects/Increased Susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including epirubicin, may result in serious or fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Avoid vaccination with a live vaccine in patients receiving Epirubicin HCl. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9     Gastrointestinal</h2>
<p class="First">Epirubicin HCl is emetigenic. Antiemetics may reduce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of antiemetics should be considered before administration of Epirubicin HCl, particularly when given in conjunction with other emetigenic drugs <span class="Italics">[see <a href="#S6">Adverse Reactions (6.X)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10    <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> and Thromboembolic Phenomena</h2>
<p class="First">As with other cytotoxic agents, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> and thromboembolic phenomena, including <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (in some cases fatal) have been coincidentally reported with the use of Epirubicin HCl.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11     Coadministration with Cimetidine</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Cimetidine increased the AUC of epirubicin by 50%. Stop Cimetidine treatment during treatment with Epirubicin HCl.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]</span></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	Pregnancy</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Epirubicin HCl can cause fetal harm when administered to a pregnant woman. Epirubicin was embryolethal and teratogenic in rats and rabbits. There are no adequate and well-controlled studies of Epirubicin HCl in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. <span class="Italics">[see <a href="#S8.1">Use In Specific Populations (8.1)</a>]</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13    Male Fertility and Reproductive Outcomes</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Males with female sexual partners of childbearing potential should use contraception during and after cessation of Epirubicin HCl therapy. Epirubicin HCl may damage testicular tissue and spermatozoa. Possible sperm DNA damage raises concerns about loss of fertility and genetic abnormalities in fetuses. The duration of this effect is uncertain. <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span></span></p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14    Laboratory Testing</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Assess blood counts, including absolute neutrophil counts, and liver function before and during each cycle of therapy with Epirubicin HCl. Perform repeated evaluations of LVEF during therapy. <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5</a> and <a href="#S5.6">5.6)</a>]</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15    <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> following Irradiation</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">As with other anthracyclines, administration of Epirubicin HCl after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1      Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may  not reflect the rates observed in practice.</p>
<p>Integrated safety data are available from two studies (Studies MA-5 and GFEA-05) <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span> evaluating Epirubicin HCl-containing combination regimens in patients with early breast cancer. Of the 1260 patients treated in these studies, 620 patients received the higher-dose Epirubicin HCl regimen (FEC-100/CEF-120), 280 patients received the lower-dose Epirubicin HCl regimen (FEC-50), and 360 patients received CMF. Serotonin-specific antiemetic therapy and colony-stimulating factors were not used in these trials. Clinically relevant acute adverse events are summarized in Table 2. </p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Clinically Relevant Acute Adverse Events in Patients with Early Breast Cancer</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="First Toprule">
<th class="Rrule" align="left" rowspan="4">Event</th>
<th class="Botrule Toprule" align="center" colspan="6">% of Patients</th>
</tr>
<tr>
<th class="Rrule" align="center" colspan="2">FEC-100/CEF-120</th>
<th class="Rrule" align="center" colspan="2">FEC-50</th>
<th align="center" colspan="2">CMF</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="2">(N=620)</th>
<th class="Rrule" align="center" colspan="2">(N=280)</th>
<th align="center" colspan="2">(N=360)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Grades  1–4</th>
<th class="Rrule Toprule" align="center">Grades  3/4</th>
<th class="Rrule" align="center">Grades  1–4</th>
<th class="Rrule" align="center">Grades  3/4</th>
<th class="Rrule" align="center">Grades  1–4</th>
<th align="center">Grades  3/4</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="7">FEC &amp; CEF = cyclophosphamide + Epirubicin HCl + fluorouracil; CMF = cyclophosphamide + methotrexate + fluorouracil; NA = not available</td></tr>
<tr class="Last"><td align="left" colspan="7">Grade 1 or 2 changes in transaminase levels were observed but were more frequently seen with CMF than with CEF.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left"><span class="Bold">Hematologic</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Rrule" align="center">80.3</td>
<td class="Rrule" align="center">58.6</td>
<td class="Rrule" align="center">49.6</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">98.1</td>
<td align="center">60.3</td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">80.3</td>
<td class="Rrule" align="center">67.2</td>
<td class="Rrule" align="center">53.9</td>
<td class="Rrule" align="center">10.5</td>
<td class="Rrule" align="center">95.8</td>
<td align="center">78.1</td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">72.2</td>
<td class="Rrule" align="center">5.8</td>
<td class="Rrule" align="center">12.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">70.9</td>
<td align="center">0.9</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">48.8</td>
<td class="Rrule" align="center">5.4</td>
<td class="Rrule" align="center">4.6</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">51.4</td>
<td align="center">3.6</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Endocrine</span></td>
<td class="Rrule" align="center">71.8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">69.3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">67.7</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></td>
<td class="Rrule" align="center">38.9</td>
<td class="Rrule" align="center">4.0</td>
<td class="Rrule" align="center">5.4</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">69.1</td>
<td align="center">6.4</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Body as a Whole</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Rrule" align="center">45.8</td>
<td class="Rrule" align="center">1.9</td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">72.7</td>
<td align="center">0.3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">5.2</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1.4</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4.5</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Gastrointestinal</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Rrule" align="center">92.4</td>
<td class="Rrule" align="center">25.0</td>
<td class="Rrule" align="center">83.2</td>
<td class="Rrule" align="center">22.1</td>
<td class="Rrule" align="center">85.0</td>
<td align="center">6.4</td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucositis</span></td>
<td class="Rrule" align="center">58.5</td>
<td class="Rrule" align="center">8.9</td>
<td class="Rrule" align="center">9.3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">52.9</td>
<td align="center">1.9</td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">24.8</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">7.1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">50.7</td>
<td align="center">2.8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">2.9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5.8</td>
<td align="center">0.3</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center">21.5</td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">15.0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">25.9</td>
<td align="center">0.6</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">6.1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">NA</td>
<td align="center">1.1</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Ocular</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>/<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span></td>
<td class="Rrule" align="center">14.8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1.1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">38.4</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Skin</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">95.5</td>
<td class="Rrule" align="center">56.6</td>
<td class="Rrule" align="center">69.6</td>
<td class="Rrule" align="center">19.3</td>
<td class="Rrule" align="center">84.4</td>
<td align="center">6.7</td>
</tr>
<tr>
<td class="Rrule" align="left">  Local toxicity</td>
<td class="Rrule" align="center">19.5</td>
<td class="Rrule" align="center">0.3</td>
<td class="Rrule" align="center">2.5</td>
<td class="Rrule" align="center">0.4</td>
<td class="Rrule" align="center">8.1</td>
<td align="center">0</td>
</tr>
<tr>
<td class="Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span></td>
<td class="Rrule" align="center">8.9</td>
<td class="Rrule" align="center">0.3</td>
<td class="Rrule" align="center">1.4</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">14.2</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  Skin changes</td>
<td class="Rrule" align="center">4.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">7.2</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Delayed Events</span></p>
<p>Table 3 describes the incidence of delayed adverse events in patients participating in the MA-5 and GFEA-05 trials.</p>
<a name="t3"></a><table width="90%">
<caption><span>Table 3. Long-Term Adverse Events in Patients with Early Breast Cancer</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="26%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="First">
<th class="Rrule" align="left"></th>
<th class="Botrule" align="center" colspan="3">% of Patients</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left">Event</th>
<th class="Rrule" align="center">FEC-100/CEF-120<br>(N=620)</th>
<th class="Rrule" align="center">FEC-50<br>(N=280)</th>
<th align="center">CMF<br>(N=360)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">Two cases of <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoid leukemia</span> (ALL) were also observed in patients receiving Epirubicin HCl. However, an association between anthracyclines such as Epirubicin HCl and ALL has not been clearly established.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>In study MA-5, cardiac function was not monitored after 5 years.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left"><span class="Bold">Cardiac events</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">Asymptomatic drops in LVEF</td>
<td class="Rrule" align="center">2.1<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">1.4</td>
<td align="center">0.8<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">CHF</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">0.4</td>
<td align="center">0.3</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">AML</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0</td>
<td align="center">0.3</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Overview of Acute and Delayed Toxicities</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics">Hematologic </span></p>
<p>Dose-dependent, reversible <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is the predominant manifestation of hematologic toxicity associated with Epirubicin HCl and represents the most common acute dose-limiting toxicity of this drug. In most cases, the white blood cell (WBC) nadir is reached 10 to 14 days from drug administration. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is usually transient, with WBC and neutrophil counts generally returning to normal values by Day 21 after drug administration. As with other cytotoxic agents, Epirubicin HCl at the recommended dose in combination with cyclophosphamide and fluorouracil can produce severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> may also occur. Clinical consequences of severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, tissue <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, symptomatic <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If myelosuppressive complications occur, use appropriate supportive measures (e.g., intravenous antibiotics, colony-stimulating factors, transfusions). <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> requires careful monitoring. Assess total and differential WBC, red blood cell (RBC), and platelet counts before and during each cycle of therapy with Epirubicin HCl <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Italics">Gastrointestinal </span></p>
<p>A dose-dependent <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> (mainly oral <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, less often <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>) may occur in patients treated with Epirubicin HCl. Clinical manifestations of <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> may include a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, erosions, ulcerations, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucositis</span> generally appears early after drug administration and, if severe, may progress over a few days to <span class="product-label-link" type="condition" conceptid="442121" conceptname="Mucosal ulcer">mucosal ulcerations</span>; most patients recover from this adverse event by the third week of therapy. Hyperpigmentation of the oral mucosa may also occur. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and occasionally <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> can also occur. Severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may produce <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Antiemetics may reduce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; consider <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of antiemetics before therapy <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Italics">Cutaneous and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </span></p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> occurs frequently, but is usually reversible, with hair regrowth occurring within 2 to 3 months from the termination of therapy. Flushes, skin and nail hyperpigmentation, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to irradiated skin (radiation-recall reaction) have been observed. <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported in patients treated with Epirubicin HCl; signs and symptoms of these reactions may vary from <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> to <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.4"></a><p></p>
<p class="First"><span class="Italics">Cardiovascular </span></p>
<p>In a retrospective survey, including 9144 patients, mostly with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> in advanced stages, the probability of developing CHF increased with increasing cumulative doses of Epirubicin HCl (Figure 1). The estimated risk of Epirubicin HCl-treated patients developing clinically evident CHF was 0.9% at a cumulative dose of 550 mg/m<span class="Sup">2</span>, 1.6% at 700 mg/m<span class="Sup">2</span>, and 3.3% at 900 mg/m<span class="Sup">2</span>. The risk of developing CHF in the absence of other cardiac risk factors increased steeply after an Epirubicin HCl cumulative dose of 900 mg/m<span class="Sup">2 </span><span class="Italics"> [see <a href="#S5.4">Warnings and Precautions (5.4)</a>].</span></p>
<table width="100%">
<col align="left" valign="top" width="100%">
<thead><tr class="First Last Toprule"><th align="left">Figure 1. Risk of CHF in 9144 Patients Treated with Epirubicin HCl</th></tr></thead>
<tbody><tr class="Botrule First Last Toprule"><td align="left"><p class="First"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-01.jpg"></p></td></tr></tbody>
</table>
<p>In another retrospective survey of 469 Epirubicin HCl-treated patients with metastatic or early breast cancer, the reported risk of CHF was comparable to that observed in the larger study of over 9000 patients<span class="Italics"> [see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.5"></a><p></p>
<p class="First"><span class="Italics">Secondary <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span></span></p>
<p>An analysis of 7110 patients who received adjuvant treatment with Epirubicin HCl in controlled clinical trials as a component of poly-chemotherapy regimens for early breast cancer, showed a cumulative risk of secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> or <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (AML/MDS) of about 0.27% (approximate 95% CI, 0.14–0.40) at 3 years, 0.46% (approximate 95% CI, 0.28–0.65) at 5 years, and 0.55% (approximate 95% CI, 0.33–0.78) at 8 years. The risk of developing AML/MDS increased with increasing Epirubicin HCl cumulative doses as shown in Figure 2.</p>
<table width="100%">
<col align="left" valign="top" width="100%">
<thead><tr class="First Last Toprule"><th align="left">Figure 2. Risk of AML/MDS in 7110 Patients Treated with Epirubicin HCl</th></tr></thead>
<tbody><tr class="Botrule First Last Toprule"><td align="left"><p class="First"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-02.jpg"></p></td></tr></tbody>
</table>
<p>The cumulative probability of developing AML/MDS was found to be particularly increased in patients who received more than the maximum recommended cumulative dose of Epirubicin HCl (720 mg/m<span class="Sup">2</span>) or cyclophosphamide (6,300 mg/m<span class="Sup">2</span>), as shown in Table 1.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Cumulative Probability of AML/MDS in Relation to Cumulative Doses of Epirubicin HCl and Cyclophosphamide</span></caption>
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="3">Years from Treatment Start</th>
<th class="Botrule Rrule" align="center" colspan="4">Cumulative Probability of Developing AML/MDS<br>% (95% CI)</th>
</tr>
<tr class="Botrule">
<th class="Rrule" align="center" colspan="2">Cyclophosphamide Cumulative Dose<br>≤6,300 mg/m<span class="Sup">2</span>
</th>
<th class="Rrule" align="center" colspan="2">Cyclophosphamide Cumulative Dose<br>&gt;6,300 mg/m<span class="Sup">2</span>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Epirubicin HCl Cumulative Dose<br>≤720 mg/m<span class="Sup">2</span><br>N=4760</th>
<th class="Rrule" align="center">Epirubicin HCl Cumulative Dose<br>&gt;720 mg/m<span class="Sup">2</span><br>N=111</th>
<th class="Rrule" align="center">Epirubicin HCl Cumulative Dose<br>≤720 mg/m<span class="Sup">2</span><br>N=890</th>
<th class="Rrule" align="center">Epirubicin HCl Cumulative Dose<br>&gt;720 mg/m<span class="Sup">2</span><br>N=261</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">3</td>
<td class="Rrule" align="center">0.12 (0.01–0.22)</td>
<td class="Rrule" align="center">0.00 (0.00–0.00)</td>
<td class="Rrule" align="center">0.12 (0.00–0.37)</td>
<td class="Rrule" align="center">4.37 (1.69–7.05)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">5</td>
<td class="Rrule" align="center">0.25 (0.08–0.42)</td>
<td class="Rrule" align="center">2.38 (0.00–6.99)</td>
<td class="Rrule" align="center">0.31 (0.00–0.75)</td>
<td class="Rrule" align="center">4.97 (2.06–7.87)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">8</td>
<td class="Rrule" align="center">0.37 (0.13–0.61)</td>
<td class="Rrule" align="center">2.38 (0.00–6.99)</td>
<td class="Rrule" align="center">0.31 (0.00–0.75)</td>
<td class="Rrule" align="center">4.97 (2.06–7.87)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.6"></a><p></p>
<p class="First"><span class="Bold">Injection-Site Reactions </span><span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1   Cardioactive Compounds</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Do not administer Epirubicin in combination with other cardiotoxic agents unless the patient's cardiac function is closely monitored. Patients receiving epirubicin after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, may also be at an increased risk of developing cardiotoxicity. Avoid epirubicin-based therapy for up to 24 weeks after stopping trastuzumab when possible. If epirubicin is used before this time, monitor cardiac function carefully <span class="Italics">[see <a href="#S2">Dosage and Administration (2)</a> and <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span><span class="Bold">.</span></span></p>
<p>Concomitant use of Epirubicin HCl with other cardioactive compounds that could cause <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Cimetidine</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Cimetidiene increases the exposure to epirubicin <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span> Stop Cimetidine during treatment with Epirubicin HCl.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3    Other Cytotoxic Drugs</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Epirubicin HCl used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Paclitaxel:</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The administration of epirubicin immediately prior to or after paclitaxel increased the systemic exposure of epirubicin, epirubicinol and 7-deoxydoxorubicin aglycone <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Docetaxel:</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The administration of epirubicin immediately prior to or after docetaxel did not have an effect on the systemic exposure of epirubicin, but increased the systemic exposure of epirubicinol and 7-deoxydoxorubicin aglycone <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4     Radiation Therapy</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There are few data regarding the coadministration of radiation therapy and Epirubicin HCl. In adjuvant trials of Epirubicin HCl-containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed. This practice resulted in no apparent increase in local breast cancer recurrence relative to published accounts in the literature. A small number of patients received Epirubicin HCl-based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities. It is likely that use of Epirubicin HCl with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation. Administration of Epirubicin HCl after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5     Concomitant Therapies-Hepatic Function</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Epirubicin is extensively metabolized by the liver. Changes in hepatic function induced by concomitant therapies may affect epirubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity.</span></p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6       Drug/Laboratory Test Interactions</h2>
<p class="First">There are no known interactions between Epirubicin HCl and laboratory tests.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category D. See '<a href="#S5">Warnings and Precautions</a>' section.</p>
<p>Epirubicin HCl can cause fetal harm when administered to a pregnant woman. Administration of 0.8 mg/kg/day intravenously of epirubicin to rats (about 0.04 times the maximum recommended single human dose on a body surface area basis) during Days 5 to 15 of gestation was embryotoxic (increased resorptions and post-implantation loss) and caused <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> (decreased body weight), but was not teratogenic up to this dose. Administration of 2 mg/kg/day intravenously of epirubicin to rats (about 0.1 times the maximum recommended single human dose on a body surface area basis) on Days 9 and 10 of gestation was embryotoxic (increased late resorptions, post-implantation losses, and dead fetuses; and decreased live fetuses), retarded fetal growth (decreased body weight), and caused decreased placental weight. This dose was also teratogenic, causing numerous external (<span class="product-label-link" type="condition" conceptid="4004155" conceptname="Anal atresia">anal atresia</span>, misshapen tail, abnormal genital tubercle), visceral (primarily gastrointestinal, urinary, and cardiovascular systems), and skeletal (deformed long bones and girdles, rib abnormalities, irregular spinal ossification) malformations. Administration of intravenous epirubicin to rabbits at doses up to 0.2 mg/kg/day (about 0.02 times the maximum recommended single human dose on a body surface area basis) during Days 6 to 18 of gestation was not embryotoxic or teratogenic, but a maternally toxic dose of 0.32 mg/kg/day increased abortions and delayed ossification. Administration of a maternally toxic intravenous dose of 1 mg/kg/day epirubicin to rabbits (about 0.1 times the maximum recommended single human dose on a body surface area basis) on Days 10 to 12 of gestation induced abortion, but no other signs of embryofetal toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were observed. When doses up to 0.5 mg/kg/day epirubicin were administered to rat dams from Day 17 of gestation to Day 21 after delivery (about 0.025 times the maximum recommended single human dose on a body surface area basis), no permanent changes were observed in the development, functional activity, behavior, or reproductive performance of the offspring. </p>
<p>There are no adequate and well-controlled studies of Epirubicin HCl in pregnant women. Two pregnancies have been reported in women taking epirubicin. A 34-year-old woman, 28 weeks pregnant at her diagnosis of breast cancer, was treated with cyclophosphamide and epirubicin every 3 weeks for 3 cycles. She received the last dose at 34 weeks of pregnancy and delivered a healthy baby at 35 weeks. A second 34-year-old woman with breast cancer metastatic to the liver was randomized to FEC-50 but was removed from study because of pregnancy. She experienced a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Epirubicin was excreted into the milk of rats treated with 0.50 mg/kg/day of epirubicin during peri- and postnatal periods. It is not known whether this drug is excreted in human milk. Because many drugs, including other anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Epirubicin HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of Epirubicin HCl have not been established in pediatric patients. Pediatric patients may be at greater risk for anthracycline-induced acute manifestations of cardiotoxicity and for chronic CHF. The pharmacokinetics of epirubicin in pediatric patients have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Although a lower starting dose of Epirubicin HCl was not used in trials in elderly female patients, particular care should be taken in monitoring toxicity when Epirubicin HCl is administered to female patients ≥ 70 years of age <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Epirubicin is eliminated by both hepatic metabolism and biliary excretion and clearance is reduced in patients with hepatic dysfunction.. Do not treat patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> with Epirubicin HCl. Reduce the starting dose for patients with less severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see  <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7   <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No significant alterations in the pharmacokinetics of epirubicin or its major metabolite, epirubicinol, have been observed in patients with serum creatinine &lt; 5 mg/dL. Consider lower doses in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (serum creatinine &gt; 5 mg/dL), as a reduction in plasma clearance was reported in these patients <span class="Italics">[see, <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a> ].</span> Patients on dialysis have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of Epirubicin HCl. A 36-year-old man with non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> received a daily 95 mg/m<span class="Sup">2</span> dose of Epirubicin HCl Injection for 5 consecutive days. Five days later, he developed bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, grade 4 <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. No signs of acute cardiac toxicity were observed. He was treated with antibiotics, colony-stimulating factors, and antifungal agents, and recovered completely. A 63-year-old woman with breast cancer and liver <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> received a single 320 mg/m<span class="Sup">2</span> dose of Epirubicin HCl. She was hospitalized with <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> and developed <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiple organ failure</span> (respiratory and renal), with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, increased lactate dehydrogenase, and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> occurred within 24 hours after administration of Epirubicin HCl. Additional instances of administration of doses higher than recommended have been reported at doses ranging from 150 to 250 mg/m<span class="Sup">2</span>. The observed adverse events in these patients were qualitatively similar to known toxicities of epirubicin. Most of the patients recovered with appropriate supportive care.</p>
<p>If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, provide supportive treatment (including antibiotic therapy, blood and platelet transfusions, colony-stimulating factors, and intensive care as needed) until the recovery of toxicities. Delayed CHF has been observed months after anthracycline administration. Observe patients carefully over time for signs of CHF and provided with appropriate supportive therapy.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Epirubicin HCl Injection (epirubicin hydrochloride injection) is an anthracycline cytotoxic agent, intended for intravenous administration. Epirubicin HCl is supplied as a sterile, clear, red solution and is available in polypropylene vials containing 50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride. Inactive ingredients include sodium chloride, USP, and water for injection, USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid, NF.</p>
<p>Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic derivative of daunorubicin. The chemical name is (8S-<span class="Bold Italics">cis</span>)-10-[(3-amino-2,3,6-trideoxy-α-L- <span class="Bold Italics">arabino</span>-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride. The active ingredient is a red-orange hygroscopic powder, with the empirical formula C<span class="Sub">27 </span>H<span class="Sub">29 </span>NO<span class="Sub">11</span> HCl and a molecular weight of 579.95. The structural formula is as follows:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated.</p>
<p>Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis.</p>
<p>Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms.</p>
<p>Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">Epirubicin pharmacokinetics are linear over the dose range of 60 to 150 mg/m<span class="Sup">2</span> and plasma clearance is not affected by the duration of infusion or administration schedule. Pharmacokinetic parameters for epirubicin following 6- to 10-minute, single-dose intravenous infusions of Epirubicin HCl at doses of 60 to 150 mg/m<span class="Sup">2</span> in patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> are shown in Table 4. The plasma concentration declined in a triphasic manner with mean half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours, and 33 hours, respectively.</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4. Summary of Mean (±SD) Pharmacokinetic Parameters in Patients <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span> Receiving Intravenous Epirubicin HCl 60 to 150 mg/m<span class="Sup">2</span></span></caption>
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<thead><tr class="First Last">
<th class="Rrule" align="center">Dose <a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a><br>(mg/m<span class="Sup">2</span> )</th>
<th class="Rrule" align="center">C<span class="Sub">max</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a><br>(µg/mL)</th>
<th class="Rrule" align="center">AUC <a name="footnote-reference-5" href="#footnote-5" class="Sup">§</a><br>(µg•h/mL)</th>
<th class="Rrule" align="center">t<span class="Sub">1/2</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">¶</a><br>(hours)</th>
<th class="Rrule" align="center">CL<a name="footnote-reference-7" href="#footnote-7" class="Sup">#</a><br>(L/hour)</th>
<th align="center">Vss<a name="footnote-reference-8" href="#footnote-8" class="Sup">Þ</a><br>(L/kg)</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Advanced <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumor</span> cancers, primarily of the lung</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>N=6 patients per dose level</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>Plasma concentration at the end of 6 to 10 minute infusion</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">§</a></dt>
<dd>Area under the plasma concentration curve</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">¶</a></dt>
<dd>Half-life of terminal phase</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">#</a></dt>
<dd>Plasma clearance</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">Þ</a></dt>
<dd>Steady state volume of distribution</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="center">60</td>
<td class="Rrule" align="center">5.7 ± 1.6</td>
<td class="Rrule" align="center">1.6 ± 0.2</td>
<td class="Rrule" align="center">35.3 ± 9</td>
<td class="Rrule" align="center">65 ± 8</td>
<td align="center">21 ± 2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">75</td>
<td class="Rrule" align="center">5.3 ± 1.5</td>
<td class="Rrule" align="center">1.7 ± 0.3</td>
<td class="Rrule" align="center">32.1 ± 5</td>
<td class="Rrule" align="center">83 ± 14</td>
<td align="center">27 ± 11</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">120</td>
<td class="Rrule" align="center">9.0 ± 3.5</td>
<td class="Rrule" align="center">3.4 ± 0.7</td>
<td class="Rrule" align="center">33.7 ± 4</td>
<td class="Rrule" align="center">65 ± 13</td>
<td align="center">23 ± 7</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center">150</td>
<td class="Rrule" align="center">9.3 ± 2.9</td>
<td class="Rrule" align="center">4.2 ± 0.8</td>
<td class="Rrule" align="center">31.1 ± 6</td>
<td class="Rrule" align="center">69 ± 13</td>
<td align="center">21 ± 7</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Following intravenous administration, epirubicin is rapidly and widely distributed into the tissues. Binding of epirubicin to plasma proteins, predominantly albumin, is about 77% and is not affected by drug concentration. Epirubicin also appears to concentrate in red blood cells; whole blood concentrations are approximately twice those of plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Epirubicin is extensively and rapidly metabolized by the liver and is also metabolized by other organs and cells, including red blood cells. Four main metabolic routes have been identified:</p>
<p>(1) reduction of the C-13 keto-group with the formation of the 13(S)-dihydro derivative, epirubicinol; (2) conjugation of both the unchanged drug and epirubicinol with glucuronic acid; (3) loss of the amino sugar moiety through a hydrolytic process with the formation of the doxorubicin and doxorubicinol aglycones; and (4) loss of the amino sugar moiety through a redox process with the formation of the 7-deoxy-doxorubicin aglycone and 7-deoxy-doxorubicinol aglycone. Epirubicinol has in vitro cytotoxic activity one-tenth that of epirubicin. As plasma levels of epirubicinol are lower than those of the unchanged drug, they are unlikely to reach in vivo concentrations sufficient for cytotoxicity. No significant activity or toxicity has been reported for the other metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Italics">Excretion.</span></p>
<p>Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion. <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span>-balance data from 1 patient found about 60% of the total radioactive dose in feces (34%) and urine (27%). These data are consistent with those from 3 patients with extrahepatic obstruction and percutaneous drainage, in whom approximately 35% and 20% of the administered dose were recovered as epirubicin or its major metabolites in bile and urine, respectively, in the 4 days after treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Italics">Effect of Age</span></p>
<p>A population analysis of plasma data from 36 cancer patients (13 males and 23 females, 20 to 73 years) showed that age affects plasma clearance of epirubicin in female patients. The predicted plasma clearance for a female patient of 70 years of age was about 35% lower than that for a female patient of 25 years of age. An insufficient number of males &gt; 50 years of age were included in the study to draw conclusions about age-related alterations in clearance in males. Although a lower Epirubicin HCl starting dose does not appear necessary in elderly female patients, and was not used in clinical trials, particular care should be taken in monitoring toxicity when Epirubicin HCl is administered to female patients &gt; 70 years of age <span class="Italics">[see <a href="#S17">Patient Counseling Information (17)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Italics">Effect of Gender</span></p>
<p>In patients ≤ 50 years of age, mean clearance values in adult male and female patients were similar. The clearance of epirubicin is decreased in elderly women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Italics">Effect of Race</span></p>
<p>The influence of race on the pharmacokinetics of epirubicin has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>\</span></p>
<p>Epirubicin is eliminated by both hepatic metabolism and biliary excretion and clearance is reduced in patients with hepatic dysfunction. In a study of the effect of hepatic dysfunction, patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> were classified into 3 groups. Patients in Group 1 (n=22) had serum AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) levels above the upper limit of normal (median: 93 IU/L) and normal serum bilirubin levels (median: 0.5 mg/dL) and were given Epirubicin HCl doses of 12.5 to 90 mg/m<span class="Sup">2</span>. Patients in Group 2 had alterations in both serum AST (median: 175 IU/L) and bilirubin levels (median: 2.7 mg/dL) and were treated with an Epirubicin HCl dose of 25 mg/m<span class="Sup">2</span> (n=8). Their pharmacokinetics were compared to those of patients with normal serum AST and bilirubin values, who received Epirubicin HCl doses of 12.5 to 120 mg/m<span class="Sup">2</span>. The median plasma clearance of epirubicin was decreased compared to patients with normal hepatic function by about 30% in patients in Group 1 and by 50% in patients in Group 2. Patients with more severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been evaluated <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, and <a href="#S5.5">Warnings and Precautions (5.5)</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.8"></a><p></p>
<p class="First"><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></p>
<p>No significant alterations in the pharmacokinetics of epirubicin or its major metabolite, epirubicinol, have been observed in patients with serum creatinine &lt; 5 mg/dL. A 50% reduction in plasma clearance was reported in four patients with serum creatinine ≥ 5 mg/dL <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a> and <a href="#S2.2">Dosing and Administration (2.2)</a>]</span>. Patients on dialysis have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.9"></a><p></p>
<p class="First"><span class="Italics">Effect of Paclitaxel</span></p>
<p>The administration of paclitaxel (175–225 mg/m<span class="Sup">2</span> as a 3-hour infusion) immediately before or after epirubicin (90 mg/m<span class="Sup">2</span> as bolus) caused variable increases in the systemic exposure (mean AUC) of epirubicin ranging from 5% to 109%. At same doses of epirubicin and paclitaxel, the mean AUC of the inactive metabolites of epirubicin (epirubicinol and 7-deoxy-aglycone) increased by 120% and 70%, respectively, when paclitaxel was immediately administered after epirubicin. Epirubicin had no effect on the exposure of paclitaxel whether it was administered before or after paclitaxel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.10"></a><p></p>
<p class="First"><span class="Italics">Effect of Docetaxel</span></p>
<p>The administration of docetaxel (70 mg/m<span class="Sup">2</span> as 1-hour infusion) immediately before or after epirubicin (90 mg/m<span class="Sup">2</span> as bolus) had no effect on the systemic exposure (mean AUC) of epirubicin. However, the mean AUC of epirubicinol and 7-deoxy-aglycone increased by 22.5% and 95%, respectively, when docetaxel was immediately administered after epirubicin compared to epirubicin alone . Epirubicin had no effect on the exposure of docetaxel whether it was administered before or after docetaxel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.11"></a><p></p>
<p class="First"><span class="Italics">Effect of Cimetidine</span></p>
<p>Coadministration of cimetidine (400 mg twice daily for 7 days starting 5 days before chemotherapy) increased the mean AUC of epirubicin (100 mg/m<span class="Sup">2</span>) by 50% and decreased its plasma clearance by 30% <span class="Bold Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.12"></a><p></p>
<p class="First"><span class="Italics">Drugs metabolized by cytochrome P-450 enzymes.</span></p>
<p>No systematic in vitro or in vivo evaluation has been performed to examine the potential for inhibition or induction by epirubicin of oxidative cytochrome P-450 isoenzymes.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Conventional long-term animal studies to evaluate the carcinogenic potential of epirubicin have not been conducted, but intravenous administration of a single 3.6 mg/kg epirubicin dose to female rats (about 0.2 times the maximum recommended human dose on a body surface area basis) approximately doubled the incidence of mammary tumors (primarily fibroadenomas) observed at 1 year. Administration of 0.5 mg/kg epirubicin intravenously to rats (about 0.025 times the maximum recommended human dose on a body surface area basis) every 3 weeks for ten doses increased the incidence of subcutaneous <span class="product-label-link" type="condition" conceptid="4012174" conceptname="Fibroma">fibromas</span> in males over an 18-month observation period. In addition, subcutaneous administration of 0.75 or 1.0 mg/kg/day (about 0.015 times the maximum recommended human dose on a body surface area basis) to newborn rats for 4 days on both the first and tenth day after birth for a total of eight doses increased the incidence of animals with tumors compared to controls during a 24-month observation period.</p>
<p>Epirubicin was mutagenic <span class="Italics">in vitro</span> to bacteria (Ames test) either in the presence or absence of metabolic activation and to mammalian cells (HGPRT assay in V79 Chinese hamster lung fibroblasts) in the absence but not in the presence of metabolic activation. Epirubicin was clastogenic <span class="Italics">in vitro</span> (chromosome aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) both in the presence and absence of metabolic activation and was also clastogenic <span class="Italics">in vivo</span> (chromosome aberration in mouse bone marrow).</p>
<p>In fertility studies in rats, males were given epirubicin daily for 9 weeks and mated with females that were given epirubicin daily for 2 weeks prior to mating and through Day 7 of gestation. When 0.3 mg/kg/day (about 0.015 times the maximum recommended human single dose on a body surface area basis) was administered to both sexes, no pregnancies resulted. No effects on mating behavior or fertility were observed at 0.1 mg/kg/day, but male rats had <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the testes and epididymis, and reduced spermatogenesis. The 0.1 mg/kg/day dose also caused embryolethality. An increased incidence of <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> was observed in these studies at 0.03 mg/kg/day (about 0.0015 times the maximum recommended human single dose on a body surface area basis). Multiple daily doses of epirubicin to rabbits and dogs also caused <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of male reproductive organs. Single 20.5 and 12 mg/kg doses of intravenous epirubicin caused <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> in mice and rats, respectively (both approximately 0.5 times the maximum recommended human dose on a body surface area basis). A single dose of 16.7 mg/kg epirubicin caused uterine <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> in rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adjuvant Treatment of Breast Cancer</h2>
<p class="First">Two randomized, open-label, multicenter studies evaluated the use of Epirubicin HCl Injection 100 to 120 mg/m<span class="Sup">2</span> in combination with cyclophosphamide and fluorouracil for the adjuvant treatment of patients with axillary-node positive breast cancer and no evidence of distant <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> (Stage II or III). Study MA-5 evaluated 120 mg/m<span class="Sup">2</span> of Epirubicin HCl per course in combination with cyclophosphamide and fluorouracil (CEF-120 regimen). This study randomized premenopausal and perimenopausal women with one or more positive lymph nodes to an Epirubicin HCl-containing CEF-120 regimen or to a CMF regimen. Study GFEA-05 evaluated the use of 100 mg/m<span class="Sup">2</span> of Epirubicin HCl per course in combination with fluorouracil and cyclophosphamide (FEC-100). This study randomized pre- and postmenopausal women to the FEC-100 regimen or to a lower-dose FEC-50 regimen. In the GFEA-05 study, eligible patients were either required to have ≥ 4 nodes involved with tumor or, if only 1 to 3 nodes were positive, to have negative estrogen- and progesterone-receptors and a histologic tumor grade of 2 or 3. A total of 1281 women participated in these studies. Patients with T4 tumors were not eligible for either study. Table 5 shows the treatment regimens that the patients received. Relapse-free survival was defined as time to occurrence of a local, regional, or distant recurrence, or disease-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients with contralateral breast cancer, second primary malignancy, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from causes other than breast cancer were censored at the time of the last visit prior to these events.</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5. Treatment Regimens Used in Phase 3 Studies of Patients with Early Breast Cancer</span></caption>
<col align="left" valign="top" width="10%">
<col align="center" valign="top" width="35%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="35%">
<thead><tr class="First Last">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">Treatment Groups</th>
<th class="Rrule" align="center">Agent</th>
<th align="center">Regimen</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>In women who underwent lumpectomy, breast irradiation was to be administered after completion of study chemotherapy.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Patients also received <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotic therapy with trimethoprim-sulfamethoxazole or fluoroquinolone for the duration of their chemotherapy.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>All women were to receive breast irradiation after the completion of chemotherapy.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left">MA-5<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">
<span class="Bold">CEF-120</span> (total, 6 cycles)<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a> N=356</td>
<td class="Rrule" align="center">Cyclophosphamide</td>
<td align="center">75 mg/m<span class="Sup">2</span> PO, d 1–14, q 28 days</td>
</tr>
<tr>
<td class="Rrule" align="left">N=716</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">Epirubicin HCl</td>
<td align="center">60 mg/m<span class="Sup">2</span> IV, d 1 &amp; 8, q 28 days</td>
</tr>
<tr>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center">
<span class="Bold">CMF</span> (total, 6 cycles) N=360</td>
<td class="Rrule" align="center">Fluorouracil</td>
<td align="center">500 mg/m<span class="Sup">2</span> IV, d 1 &amp; 8, q 28 days</td>
</tr>
<tr>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">Cyclophosphamide</td>
<td align="center">100 mg/m<span class="Sup">2</span> PO, d 1–14, q 28 days</td>
</tr>
<tr>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">Methotrexate</td>
<td align="center">40 mg/m<span class="Sup">2</span> IV, d 1 &amp; 8, q 28 days</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">Fluorouracil</td>
<td align="center">600 mg/m<span class="Sup">2</span> IV, d 1 &amp; 8, q 28 days</td>
</tr>
<tr>
<td class="Rrule" align="left">GFEA-05<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">
<span class="Bold">FEC-100 </span>(total, 6 cycles)</td>
<td class="Rrule" align="center">Fluorouracil</td>
<td align="center">500 mg/m<span class="Sup">2</span> IV, d 1, q 21 days</td>
</tr>
<tr>
<td class="Rrule" align="left">N=565</td>
<td class="Rrule" align="center">N=276</td>
<td class="Rrule" align="center">Epirubicin HCl</td>
<td align="center">100 mg/m<span class="Sup">2</span> IV, d 1, q 21 days</td>
</tr>
<tr>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">Cyclophosphamide</td>
<td align="center">500 mg/m<span class="Sup">2</span> IV, d 1, q 21 days</td>
</tr>
<tr>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center">
<span class="Bold">FEC-50</span> (total, 6 cycles)</td>
<td class="Rrule" align="center">Fluorouracil</td>
<td align="center">500 mg/m<span class="Sup">2</span> IV, d 1, q 21 days</td>
</tr>
<tr>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center">N=289</td>
<td class="Rrule" align="center">Epirubicin HCl</td>
<td align="center">50 mg/m<span class="Sup">2</span> IV, d 1, q 21 days</td>
</tr>
<tr>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center">Tamoxifen 30 mg daily ×</td>
<td class="Rrule" align="center">Cyclophosphamide</td>
<td align="center">500 mg/m<span class="Sup">2</span> IV, d 1, q 21 days</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"></td>
<td class="Rrule" align="center">3 years, postmenopausal<br>women, any receptor status</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
</tbody>
</table>
<p>In the MA-5 trial, the median age of the study population was 45 years. Approximately 60% of patients had 1 to 3 involved nodes and approximately 40% had ≥ 4 nodes involved with tumor. In the GFEA-05 study, the median age was 51 years and approximately half of the patients were postmenopausal. About 17% of the study population had 1 to 3 positive nodes and 80% of patients had ≥ 4 involved lymph nodes. Demographic and tumor characteristics were well-balanced between treatment arms in each study.</p>
<p>Relapse-free survival (RFS) and overall survival (OS) were analyzed using Kaplan-Meier methods in the intent-to-treat (ITT) patient populations in each study. Results were initially analyzed after up to 5 years of follow-up and these results are presented in the text below and in Table 3. Results after up to 10 years of follow-up are presented in Table 3. In Study MA-5, Epirubicin HCl-containing combination therapy (CEF-120) showed significantly longer RFS than CMF (5-year estimates were 62% versus 53%, stratified logrank for the overall RFS p=0.013). The estimated reduction in the risk of relapse was 24% at 5 years. The OS was also greater for the Epirubicin HCl-containing CEF-120 regimen than for the CMF regimen (5-year estimate 77% versus 70%; stratified logrank for overall survival p=0.043; non-stratified logrank p=0.13). The estimated reduction in the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 29% at 5 years.</p>
<p>In Study GFEA-05, patients treated with the higher-dose Epirubicin HCl regimen (FEC-100) had a significantly longer 5-year RFS (estimated 65% versus 52%, logrank for the overall RFS p=0.007) and OS (estimated 76% versus 65%, logrank for the overall survival p=0.007) than patients given the lower dose regimen (FEC-50). The estimated reduction in risk of relapse was 32% at 5 years. The estimated reduction in the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was 31% at 5 years. Results of follow-up up to 10 years (median follow-up = 8.8 years and 8.3 years, respectively, for Study MA-5 and Study GFEA-05) are presented in Table 6.</p>
<p>Although the trials were not powered for subgroup analyses, in the MA-5 study, improvements in favor of CEF-120 vs. CMF were observed, in RFS and OS both in patients with 1–3 node positive and in those with ≥4 node positive tumor involvement. In the GFEA-05 study, improvements in RFS and OS were observed in both pre- and postmenopausal women treated with FEC-100 compared to FEC-50.</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6. Efficacy Results from Phase 3 Studies of Patients with Early Breast Cancer<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="17%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">MA-5 Study</th>
<th class="Rrule" align="center" colspan="2">GFEA-05 Study</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">CEF-120<br>N=356</th>
<th class="Rrule" align="center">CMF<br>N=360</th>
<th class="Rrule" align="center">FEC-100<br>N=276</th>
<th class="Rrule" align="center">FEC-50<br>N=289</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>Based on Kaplan-Meier estimates</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">†</a></dt>
<dd>Hazard ratio: CMF:CEF-120 in MA-5, FEC-50:FEC-100 in GFEA-05</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">‡</a></dt>
<dd>Patients in MA-5 were stratified by nodal status (1–3, 4–10, and &gt;10 positive nodes), type of initial surgery (lumpectomy versus mastectomy), and by hormone receptor status (ER or PR positive (≥10 fmol), both negative (&lt;10 fmol), or unknown status). Patients in GFEA-05 were stratified by nodal status (1–3, 4–10, and &gt;10 positive nodes).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">RFS at 5 yrs (%)</span></td>
<td class="Rrule" align="center">62</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">65</td>
<td class="Rrule" align="center">52</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Hazard ratio<a name="footnote-reference-13" href="#footnote-13" class="Sup">†</a>
</td>
<td class="Rrule" align="center" colspan="2">0.76</td>
<td class="Rrule" align="center" colspan="2">0.68</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  2-sided 95% CI</td>
<td class="Rrule" align="center" colspan="2">(0.60, 0.96)</td>
<td class="Rrule" align="center" colspan="2">(0.52, 0.89)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Logrank Test <br>       stratified<a name="footnote-reference-14" href="#footnote-14" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">(p = 0.013)</td>
<td class="Rrule" align="center" colspan="2">(p = 0.007)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">OS at 5 yrs (%)</span></td>
<td class="Rrule" align="center">77</td>
<td class="Rrule" align="center">70</td>
<td class="Rrule" align="center">76</td>
<td class="Rrule" align="center">65</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Hazard ratio<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Rrule" align="center" colspan="2">0.71</td>
<td class="Rrule" align="center" colspan="2">0.69</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  2-sided 95% CI</td>
<td class="Rrule" align="center" colspan="2">(0.52, 0.98)</td>
<td class="Rrule" align="center" colspan="2">(0.51, 0.92)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Logrank Test<br>       stratified<a href="#footnote-14" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">(p = 0.043)<br>(unstratified p = 0.13)</td>
<td class="Rrule" align="center" colspan="2">(p = 0.007)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">RFS at 10 yrs (%)</span></td>
<td class="Rrule" align="center">51</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center">43</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Hazard ratio<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Rrule" align="center" colspan="2">0.78</td>
<td class="Rrule" align="center" colspan="2">0.78</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  2-sided 95% CI</td>
<td class="Rrule" align="center" colspan="2">(0.63, 0.95)</td>
<td class="Rrule" align="center" colspan="2">(0.62, 0.99)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Logrank Test<br>       stratified<a href="#footnote-14" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">(p = 0.017)<br>(unstratified p = 0.023)</td>
<td class="Rrule" align="center" colspan="2">(p = 0.040)<br>(unstratified p = 0.09)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">OS at 10 yrs (%)</span></td>
<td class="Rrule" align="center">61</td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">56</td>
<td class="Rrule" align="center">50</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Hazard ratio<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Rrule" align="center" colspan="2">0.82</td>
<td class="Rrule" align="center" colspan="2">0.75</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  2-sided 95% CI</td>
<td class="Rrule" align="center" colspan="2">(0.65, 1.04)</td>
<td class="Rrule" align="center" colspan="2">(0.58, 0.96)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Logrank Test<br>      stratified<a href="#footnote-14" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">(p = 0.100)<br>(unstratified p = 0.18)</td>
<td class="Rrule" align="center" colspan="2">(p = 0.023)<br>(unstratified p = 0.039)</td>
</tr>
</tbody>
</table>
<p>The Kaplan-Meier curves for RFS and OS from Study MA-5 are shown in Figures 3 and 4 and those for Study GFEA-05 are shown in Figures 5 and 6.<br> </p>
<p><span class="Bold">Figure 3. Relapse-Free Survival in Study MA-5</span><br><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-04.jpg"><br> 
								</p>
<p><span class="Bold">Figure 4. Overall Survival in Study MA-5</span><br> <img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-05.jpg"></p>
<p><span class="Bold">Figure 5. Relapse-Free Survival in Study GFEA-05</span><br> 	<img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-06.jpg"></p>
<p><span class="Bold">Figure 6. Overall Survival in Study GFEA-05</span><br> <img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-07.jpg"></p>
<p>See <a href="#t6">Table 6</a> for statistics on 5 and 10 year analyses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt class="Bold">1.</dt>
<dd>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</dd>
<dt class="Bold">2.</dt>
<dd>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. <span class="Underline">http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</span>.</dd>
<dt class="Bold">3.</dt>
<dd>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm.</span> 2006; 63:1172–1193.</dd>
<dt class="Bold">4.</dt>
<dd>Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Epirubicin HCl Injection is available in polypropylene single-use CYTOSAFE™ vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use solution in the following strengths:</p>
<table width="70%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="40%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"></td>
<td align="left">50 mg/25 mL single-use vial</td>
<td align="left">NDC 59762-5091-01</td>
</tr>
<tr class="Botrule Last">
<td align="left"></td>
<td align="left">200 mg/100 mL single-use vial</td>
<td align="left">NDC 59762-5093-01</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Store refrigerated between 2ºC and 8ºC (36ºF and 46ºF). Do not freeze. Protect from light.</p>
<p>Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15–25ºC). Solution for injection should be used within 24 hours after removal from refrigeration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Inform patients of the expected adverse effects of Epirubicin HCl, including <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and potential neutropenic complications.</p>
<p>Patients should understand that there is a risk of irreversible myocardial damage associated with treatment with Epirubicin HCl, as well as a risk of treatment-related <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>.</p>
<p>Patients should consult their physician if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, symptoms of CHF, or injection-site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> occurs following therapy with Epirubicin HCl.</p>
<p>Advise patients that their urine may appear red for 1 to 2 days after administration of Epirubicin HCl and that they should not be alarmed.</p>
<p>Because Epirubicin HCl may induce chromosomal damage in sperm, advise men undergoing treatment with Epirubicin HCl to use effective contraceptive methods. Women treated with Epirubicin HCl may develop irreversible <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, or <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-08.jpg"></p>
<p>LAB-0339-5.0</p>
<p>November 2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg/25 mL Label</span></p>
<p><span class="Bold">NDC</span> 59762-5091-1</p>
<p>GREENSTONE<span class="Sup">®</span> BRAND</p>
<p><span class="Bold">epirubicin hydrochloride<br>injection</span></p>
<p><span class="Bold">50 mg/25 mL</span></p>
<p>(2 mg/mL)<br>Single Use 25 mL Vial<br>For Intravenous<br>Use Only</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg/25 mL Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-09.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg/100 mL Label</span></p>
<p><span class="Bold">NDC</span> 59762-5093-1</p>
<p>GREENSTONE<span class="Sup">®</span> BRAND</p>
<p><span class="Bold">epirubicin hydrochloride<br>injection</span></p>
<p><span class="Bold">200 mg/100 mL</span><br>(2 mg/mL)</p>
<p>Single Use 100 mL Vial<br>For Intravenous<br>Use Only</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg/100 mL Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc0a3a39-4ac3-47de-a388-9c3672e3e130&amp;name=epirubicin-10.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EPIRUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">epirubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59762-5091</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>epirubicin hydrochloride</strong> (epirubicin) </td>
<td class="formItem">epirubicin hydrochloride</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59762-5091-1</td>
<td class="formItem">25 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA050778</td>
<td class="formItem">09/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EPIRUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">epirubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59762-5093</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>epirubicin hydrochloride</strong> (epirubicin) </td>
<td class="formItem">epirubicin hydrochloride</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59762-5093-1</td>
<td class="formItem">100 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA050778</td>
<td class="formItem">09/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Greenstone, LLC
							(825560733)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">989811526</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer (Perth) Pty Limited</td>
<td class="formItem"></td>
<td class="formItem">757868963</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Actavis Italy SPA A SOCIO UNICO</td>
<td class="formItem"></td>
<td class="formItem">857007913</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3d69a668-3124-4002-9822-84e52314c573</div>
<div>Set id: bc0a3a39-4ac3-47de-a388-9c3672e3e130</div>
<div>Version: 4</div>
<div>Effective Time: 20111115</div>
</div>
</div> <div class="DistributorName">Greenstone, LLC</div></p>
</body></html>
